NIV-话题@MedSci

#NIV#

134篇内容 | 3052人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2007844, encodeId=60aa200e84408, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab和多西他赛治疗晚期鳞状细胞非小细胞肺癌的比较, objectType=article, longId=51502, objectId=6ba85150226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ba85150226, replyNumber=0, likeNumber=67, createdTime=2015-09-01, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ba85150226, moduleTitle=NEJM：Nivolumab和多西他赛治疗晚期鳞状细胞非小细胞肺癌的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ba85150226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007850, encodeId=e110200e85053, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab应答持久性给部分患者一线生机（CheckMate 057研究）, objectType=article, longId=57738, objectId=18ff5e7388f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ff5e7388f, replyNumber=0, likeNumber=60, createdTime=2016-03-31, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ff5e7388f, moduleTitle=NEJM：Nivolumab应答持久性给部分患者一线生机（CheckMate 057研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ff5e7388f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007852, encodeId=518f200e852da, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验, objectType=article, longId=58535, objectId=9edb5853543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9edb5853543, replyNumber=0, likeNumber=47, createdTime=2016-01-15, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9edb5853543, moduleTitle=上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9edb5853543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007840, encodeId=38d1200e84097, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价, objectType=article, longId=44538, objectId=2d0144538df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0144538df, replyNumber=0, likeNumber=87, createdTime=2015-09-27, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0144538df, moduleTitle=FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0144538df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007847, encodeId=d48b200e84720, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：对NSCLC患者使用nivolumab和docetaxel药物之间的区别, objectType=article, longId=53170, objectId=75e8531e00b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e8531e00b, replyNumber=0, likeNumber=62, createdTime=2015-12-10, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e8531e00b, moduleTitle=NEJM：对NSCLC患者使用nivolumab和docetaxel药物之间的区别, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e8531e00b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007839, encodeId=9da6200e8394f, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期, objectType=article, longId=42706, objectId=31cd42e06ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31cd42e06ce, replyNumber=0, likeNumber=75, createdTime=2015-09-29, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31cd42e06ce, moduleTitle=回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31cd42e06ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007846, encodeId=77bf200e8463e, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab和易普利姆玛联合或单药治疗未经治疗过的黑色素瘤, objectType=article, longId=52809, objectId=e69952809eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69952809eb, replyNumber=0, likeNumber=75, createdTime=2015-09-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69952809eb, moduleTitle=NEJM：Nivolumab和易普利姆玛联合或单药治疗未经治疗过的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69952809eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007843, encodeId=9300200e8436f, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab联合Ipilimumab用于晚期黑素瘤疗效优于单药治疗, objectType=article, longId=49754, objectId=de8f49e54b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de8f49e54b6, replyNumber=0, likeNumber=113, createdTime=2016-03-14, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de8f49e54b6, moduleTitle=NEJM：Nivolumab联合Ipilimumab用于晚期黑素瘤疗效优于单药治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de8f49e54b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007845, encodeId=254c200e84517, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab和易普利姆玛联合治疗或单药治疗黑色素瘤, objectType=article, longId=51511, objectId=fde1515116c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde1515116c, replyNumber=0, likeNumber=76, createdTime=2016-01-01, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde1515116c, moduleTitle=NEJM：Nivolumab和易普利姆玛联合治疗或单药治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde1515116c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007838, encodeId=c81c200e8385c, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Ono公司nivolumab成为世界上**种获得上市批准抗PD-1药物, objectType=article, longId=37656, objectId=144e3e656fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=144e3e656fe, replyNumber=0, likeNumber=69, createdTime=2015-05-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=144e3e656fe, moduleTitle=Ono公司nivolumab成为世界上**种获得上市批准抗PD-1药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=144e3e656fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007835, encodeId=2d59200e835e4, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=ASCO 2014 ：检查点抑制剂nivolumab可持续缓解转移性肾细胞癌, objectType=article, longId=36635, objectId=720e36635ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=720e36635ec, replyNumber=0, likeNumber=76, createdTime=2014-12-10, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=720e36635ec, moduleTitle=ASCO 2014 ：检查点抑制剂nivolumab可持续缓解转移性肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=720e36635ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007841, encodeId=a4bf200e841a8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, objectType=article, longId=45436, objectId=04d8454369d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04d8454369d, replyNumber=0, likeNumber=74, createdTime=2015-12-03, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04d8454369d, moduleTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04d8454369d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007836, encodeId=3084200e83647, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=nivolumab黑色素瘤三期临床疗效明显提前终止, objectType=article, longId=37144, objectId=b9103e14463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9103e14463, replyNumber=0, likeNumber=59, createdTime=2014-10-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9103e14463, moduleTitle=nivolumab黑色素瘤三期临床疗效明显提前终止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9103e14463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007837, encodeId=c51b200e83790, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=施贵宝披露nivolumab临床三期研究数据, objectType=article, longId=37147, objectId=49ef3e14718, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ef3e14718, replyNumber=0, likeNumber=75, createdTime=2014-11-16, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ef3e14718, moduleTitle=施贵宝披露nivolumab临床三期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49ef3e14718)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NIV

2020-05-29

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab和多西他赛治疗晚期鳞状细胞非小细胞肺癌的比较

2015-09-01

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab应答持久性给部分患者一线生机（CheckMate 057研究）

2016-03-31

tamgche (审核中...)

前往app查看评论内容

#NIV#

上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验

2016-01-15

tamgche (审核中...)

前往app查看评论内容

#NIV#

FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价

2015-09-27

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：对NSCLC患者使用nivolumab和docetaxel药物之间的区别

2015-12-10

tamgche (审核中...)

前往app查看评论内容

#NIV#

回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期

2015-09-29

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab和易普利姆玛联合或单药治疗未经治疗过的黑色素瘤

2015-09-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab联合Ipilimumab用于晚期黑素瘤疗效优于单药治疗

2016-03-14

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab和易普利姆玛联合治疗或单药治疗黑色素瘤

2016-01-01

tamgche (审核中...)

前往app查看评论内容

#NIV#

Ono公司nivolumab成为世界上**种获得上市批准抗PD-1药物

2015-05-30

tamgche (审核中...)

前往app查看评论内容

#NIV#

ASCO 2014 ：检查点抑制剂nivolumab可持续缓解转移性肾细胞癌

2014-12-10

tamgche (审核中...)

前往app查看评论内容

#NIV#

Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时

2015-12-03

tamgche (审核中...)

前往app查看评论内容

#NIV#

nivolumab黑色素瘤三期临床疗效明显提前终止

2014-10-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

施贵宝披露nivolumab临床三期研究数据

2014-11-16

科室
- - 订阅+
  - 更多科室
工具
服务